Susan E Creary

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4660386/publications.pdf

Version: 2024-02-01

37	605	840776 11	642732 23
papers	citations	h-index	g-index

42	42	42	691
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A health literate approach to address health disparities: a virtual program for parents of children with sickle cell trait. Journal of Communication in Healthcare, 2022, 15, 112-120.	1.5	5
2	Telehealth Use Before and During the COVID-19 Pandemic Among Children with Sickle Cell Anemia. Telemedicine Journal and E-Health, 2022, 28, 1166-1171.	2.8	6
3	Impact of hydroxyurea dose and adherence on hematologic outcomes for children with sickle cell anemia. Pediatric Blood and Cancer, 2022, , e29607.	1.5	3
4	Trends in quality of care among children with sickle cell anemia. Pediatric Blood and Cancer, 2022, 69, e29446.	1.5	4
5	Fertility Testing Knowledge and Attitudes in Male Adolescents and Young Adults with SCD and Their Caregivers: A Pilot Study. Blood Advances, 2022, , .	5.2	8
6	Acceptability to and Engagement With a Virtual Sickle Cell Trait Education Program (SCTaware): Single-Center Prospective Study. JMIR Formative Research, 2022, 6, e38780.	1.4	2
7	Engaging Caregivers and Providers of Children With Sickle Cell Anemia in Shared Decision Making for Hydroxyurea: Protocol for a Multicenter Randomized Controlled Trial. JMIR Research Protocols, 2021, 10, e27650.	1.0	8
8	Primary Immunization Series Coverage of Children With Sickle Cell Disease. American Journal of Preventive Medicine, 2021, 61, 124-127.	3.0	0
9	Influenza immunization coverage of children with sickle cell disease. Vaccine, 2021, 39, 5538-5540.	3.8	2
10	Upper airway microbiome changes in children with sickle cell disease during vasoâ€occlusive and acute chest syndrome episodes. American Journal of Hematology, 2020, 95, E289.	4.1	0
11	Hydroxyurea Optimization through Precision Study (HOPS): study protocol for a randomized, multicenter trial in children with sickle cell anemia. Trials, 2020, 21, 983.	1.6	11
12	Measuring hydroxyurea adherence by pharmacy and laboratory data compared with video observation in children with sickle cell disease. Pediatric Blood and Cancer, 2020, 67, e28250.	1.5	8
13	Baseline and Disease-Induced Transcriptional Profiles in Children with Sickle Cell Disease. Scientific Reports, 2020, 10, 9013.	3.3	4
14	American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain. Blood Advances, 2020, 4, 2656-2701.	5.2	184
15	Opioid Prescription Filling Trends Among Children with Sickle Cell Disease After the Release of State-Issued Guidelines on Pain Management. Pain Medicine, 2020, 21, 2583-2592.	1.9	3
16	Progression of albuminuria in patients with sickle cell anemia: a multicenter, longitudinal study. Blood Advances, 2020, 4, 1501-1511.	5.2	28
17	Addressing Recruitment Challenges in the Engage-HU Trial in Young Children with Sickle Cell Disease. Blood, 2020, 136, 26-27.	1.4	0
18	Allocation of Treatment Responsibility and Adherence to Hydroxyurea Among Adolescents With Sickle Cell Disease. Journal of Pediatric Psychology, 2019, 44, 1196-1204.	2.1	5

#	Article	IF	Citations
19	A Multidimensional Electronic Hydroxyurea Adherence Intervention for Children With Sickle Cell Disease: Single-Arm Before-After Study. JMIR MHealth and UHealth, 2019, 7, e13452.	3.7	16
20	Diverse manifestations of acute sickle cell hepatopathy in pediatric patients with sickle cell disease: A case series. Pediatric Blood and Cancer, 2018, 65, e27060.	1.5	12
21	Venous Thromboembolism in Children with Sickle Cell Disease: A Retrospective Cohort Study. Journal of Pediatrics, 2018, 197, 186-190.e1.	1.8	19
22	Desire for parenthood and reproductive health knowledge in adolescents and young adults with sickle cell disease and their caregivers. Pediatric Blood and Cancer, 2018, 65, e26829.	1.5	26
23	Impact of erythrocytapheresis on natural anticoagulant levels in children with sickle cell disease: A pilot study. Pediatric Blood and Cancer, 2018, 66, e27588.	1.5	3
24	A pilot study of hormonal contraceptive use and bone mineral density in young women with sickle cell disease. Pediatric Blood and Cancer, 2018, 65, e27398.	1.5	0
25	Prevalence and risk factors for venous thromboembolism in children with sickle cell disease: an administrative database study. Blood Advances, 2018, 2, 285-291.	5.2	32
26	Losartan for the nephropathy of sickle cell anemia: A phaseâ€2, multicenter trial. American Journal of Hematology, 2017, 92, E520-E528.	4.1	36
27	Sickle cell trait knowledge and health literacy in caregivers who receive in-person sickle cell trait education. Molecular Genetics & Genomic Medicine, 2017, 5, 692-699.	1.2	22
28	A Retrospective Review to Determine If Children with Sickle Cell Disease Receive Hydroxyurea Monitoring. Pediatric Quality & Safety, 2017, 2, e024.	0.8	6
29	Secondhand Smoke Is an Important Modifiable Risk Factor in Sickle Cell Disease: A Review of the Current Literature and Areas for Future Research. International Journal of Environmental Research and Public Health, 2016, 13, 1131.	2.6	12
30	Hydroxyurea use in Children with Sickle Cell Disease: Do Severely Affected Patients Use It and Does It Impact Hospitalization Outcomes?. Pediatric Blood and Cancer, 2016, 63, 844-847.	1.5	11
31	Thrombocytopenia Pitfalls: Misdiagnosing Type 2B von Willebrand Disease as Ethylenediaminetetraacetic Acidâ˜Dependent Pseudothrombocytopenia. Journal of Pediatrics, 2016, 175, 238-238.e1.	1.8	3
32	ENHANCEâ€"(Electronic Hydroxyurea Adherence): A Protocol to Increase Hydroxyurea Adherence in Patients with Sickle Cell Disease. JMIR Research Protocols, 2016, 5, e193.	1.0	14
33	A Multi-Center, Phase-2 Trial of Losartan for the Nephropathy of Sickle Cell Anemia. Blood, 2016, 128, 265-265.	1.4	10
34	Hydroxyurea therapy for children with sickle cell disease: describing how caregivers make this decision. BMC Research Notes, 2015, 8, 372.	1.4	14
35	Identification of Unique, Heterozygous Germline Mutation, STK11 (p.F354L), in a Child with an Encapsulated Follicular Variant of Papillary Thyroid Carcinoma within Six Months of Completing Treatment for Neuroblastoma. Pediatric and Developmental Pathology, 2015, 18, 318-323.	1.0	16
36	A pilot study of electronic directly observed therapy to improve hydroxyurea adherence in pediatric patients with sickleâ€cell disease. Pediatric Blood and Cancer, 2014, 61, 1068-1073.	1.5	62

#	Article	IF	Citations
37	Prodromal Illness Before Acute Chest Syndrome in Pediatric Patients With Sickle Cell Disease. Journal of Pediatric Hematology/Oncology, 2014, 36, 480-483.	0.6	9